Simone Biles joins Arcutis’ skin campaign. Quarterly product sales were $143.9 million.
Arcutis Biotherapeutics reported Q3 2026 net product sales of $143.9M, up 45% YoY and 11% QoQ, driven by ZORYVE demand. The company raised 2026 sales guidance to $535M-$545M. Arcutis partnered with Simone Biles for a skin awareness campaign and expects Phase 2 trial results for ZORYVE foam in vitiligo by year-end. Q3 operating cash flow was $18.9M.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise provide a fresh catalyst for the stock.
Market read
Strong quarterly performance and higher guidance may drive ARQT higher in the near term.
What to watch
Potential regulatory delays for new ZORYVE indications could temper upside.
Background
Arcutis Biotherapeutics reported Q3 2026 results and raised full‑year sales guidance.
Ticker impact
Q3 product sales $143.9M (+45% YoY) and full‑year 2026 guidance raised to $535‑$545M.
likely upward as market prices in higher revenue outlook
Revenue growth and raised guidance are fresh primary disclosures that can move the stock.
Market effects
Strengthens outlook for immuno‑dermatology biotech sector.
Positive for US biotech equities.
Limited to biotech investors; no broad market effect.
Counterpoint
If guidance is overly optimistic, the stock could face disappointment on later data.
Key entities
- companyArcutis Biotherapeutics, Inc.
Commercial‑stage biotech focused on immuno‑dermatology.

